Disc Medicine, Inc. (NASDAQ: IRON) is a Healthcare company (Biotechnology) with a market capitalization of $2.9B. The Maz Rating grades it against the other companies in its sector.
Disc Medicine, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $76.57, Disc Medicine, Inc. trades at 4.9x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -36.3%, return on invested capital of -39.9% and a free cash flow yield of -6.5%. On the balance sheet: a debt-to-equity ratio of 0.10 and a current ratio of 20.30. Over the past 52 weeks the share price ranged from $40.00 to $99.50, with a beta of 2.01.
Disc Medicine, Inc. does not currently pay a dividend.
11 Wall Street analyst ratings cover the stock: 1 Strong Buy and 10 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from serious hematological diseases. The company is actively constructing a pipeline of drug candidates, designed to address a variety of these conditions by precisely targeting fundamental biological mechanisms related to red blood cell biology, particularly heme biosynthesis and iron homeostasis.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Disc Medicine, Inc. (IRON) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 2.10% / 30% · (Cash+Inv) / Mkt Cap (36m) 24.0% / 30% · Interest income / Revenue 645400000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 2.10% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 24.0% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 645400000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 2.10% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 24.0% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 645400000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 5.04% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 97.7% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 645400000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 8.54% / 33.33% · (Cash+ST Inv) / Total Assets 97.6% / 33.33% · (Cash+Recv) / Total Assets 97.6% / 33.33% · Interest income / Revenue 645400000.0% / 5% | Fail |
No. As of September 2026, Disc Medicine, Inc. (IRON) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Disc Medicine, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 645400000.0% of each dividend: Disc Medicine, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.